| Literature DB >> 31166758 |
Ajay Kohli1, Vidur Mahajan2, Kevin Seals3, Ajit Kohli4, Saurabh Jha5.
Abstract
OBJECTIVE. Although extensive attention has been focused on the enormous potential of artificial intelligence (AI) technology, a major question remains: how should this fundamentally new technology be regulated? The purpose of this article is to provide an overview of the pathways developed by the U.S. Food and Drug Administration to regulate the incorporation of AI in medical imaging. CONCLUSION. AI is the new wave of innovation in health care. The technology holds promising applications to revolutionize all aspects of medicine.Keywords: Food and Drug Administration; artificial intelligence
Year: 2019 PMID: 31166758 DOI: 10.2214/AJR.18.20410
Source DB: PubMed Journal: AJR Am J Roentgenol ISSN: 0361-803X Impact factor: 3.959